Blockchain Registration Transaction Record

Onco-Innovations CMO Highlights ONC010 PNKP Inhibitor in Podcast

Onco-Innovations CMO Dr. Islam Mohamed discusses ONC010, a novel PNKP inhibitor with dual selectivity, and its promising preclinical results in cancer treatment.

This news matters because it shines a light on a novel approach to cancer treatment that could overcome limitations of existing therapies. By targeting PNKP, a key enzyme in DNA repair, ONC010 aims to selectively kill cancer cells while sparing healthy tissue—a long-sought goal in oncology. The preclinical success of the nano-formulated inhibitor, including antitumor activity and improved survival in animal models, offers hope for patients with cancers that have limited treatment options. If ONC010 proves safe and effective in human trials, it could represent a significant breakthrough in precision oncology, particularly for tumors with PTEN or SHP-1 deficiencies. Moreover, the collaboration between Onco-Innovations and academic researchers exemplifies the translational research needed to bring innovative therapies from bench to bedside. For investors, this progress signals potential value creation as the company advances toward clinical milestones. Ultimately, the development of ONC010 could contribute to the broader fight against cancer, where new mechanisms of action are urgently needed to address resistance and improve outcomes.